The study results suggested that emicizumab prophylaxis administered subcutaneously following four loading doses weekly, led to a significant reduction in the bleeding rate compared with no prophylaxis among hemophilia A patients, regardless of the presence of FVIII inhibitors. This evidence concerns the gene F8 and hemophilia A.